patient with asymptomatic covid-19 infection. patient who has experienced the onset of any of covid-19 symptoms > 5 days at the time of randomization. moderate to severe covid-19 infection patient with covid-19 re-infection subjects who are severely immunocompromised subjects with autoimmune diseases patients with any bleeding disorder e.g., hemophilia and von willebrand disease. current use of other dhodh inhibitors including teriflunomide or leflunomide. patients who are on or immediately require covid-19 directed treatment such as antivirals, immunomodulatory treatment, convalescent plasma, oral/ intravenous steroids, or monoclonal antibodies at the time of screening. patients who have had received one or two doses of vaccine for covid-19. patients participating in another clinical study or use of any investigational product within 4 weeks or 5 half-lives of the drug, whichever is longer, before the date of dosing

patient with asymptomatic covid-19 infection. patient who has experienced the onset of any of covid-19 symptoms > 5 days at the time of randomization. moderate to severe covid-19 infection patient with covid-19 re-infection subjects who are severely immunocompromised subjects with autoimmune diseases patients with any bleeding disorder e.g., hemophilia and von willebrand disease. current use of other dhodh inhibitors including teriflunomide or leflunomide. patients who are on or immediately require covid-19 directed treatment such as antivirals, immunomodulatory treatment, convalescent plasma, oral/ intravenous steroids, or monoclonal antibodies at the time of screening. patients who have had received one or two doses of vaccine for covid-19. patients participating in another clinical study or use of any investigational product within 4 weeks or 5 half-lives of the drug, whichever is longer, before the date of dosing

1. patient with asymptomatic covid-19 infection. 2. patient who has experienced the onset of any of covid-19 symptoms > 5 days at the time of randomization. 3. moderate to severe covid-19 infection 4. patient with covid-19 re-infection 5. subjects who are severely immunocompromised 6. subjects with autoimmune diseases 7. patients with any bleeding disorder e.g., hemophilia and von willebrand disease. 8. current use of other dhodh inhibitors including teriflunomide or leflunomide. 9. patients who are on or immediately require covid-19 directed treatment such as antivirals, immunomodulatory treatment, convalescent plasma, oral/ intravenous steroids, or monoclonal antibodies at the time of screening. 10. patients who have had received one or two doses of vaccine for covid-19. 11. patients participating in another clinical study or use of any investigational product within 4 weeks or 5 half-lives of the drug, whichever is longer, before the date of dosing

1. patient with asymptomatic covid-19 infection. 2. patient who has experienced the onset of any of covid-19 symptoms > 5 days at the time of randomization. 3. moderate to severe covid-19 infection 4. patient with covid-19 re-infection 5. subjects who are severely immunocompromised 6. subjects with autoimmune diseases 7. patients with any bleeding disorder e.g., hemophilia and von willebrand disease. 8. current use of other dhodh inhibitors including teriflunomide or leflunomide. 9. patients who are on or immediately require covid-19 directed treatment such as antivirals, immunomodulatory treatment, convalescent plasma, oral/ intravenous steroids, or monoclonal antibodies at the time of screening. 10. patients who have had received one or two doses of vaccine for covid-19. 11. patients participating in another clinical study or use of any investigational product within 4 weeks or 5 half-lives of the drug, whichever is longer, before the date of dosing